Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
about
Recent advances in the development of Aurora kinases inhibitors in hematological malignanciesDevelopment of cell-cycle checkpoint therapy for solid tumorsContinuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia.Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX models.
P2860
Q26775723-8E56506F-59D6-426D-9991-7415B52B79A1Q26781187-45055BB1-9225-4CB2-AE4B-DF7400CBD33BQ37376481-FC069D4C-AF0C-47E0-84A3-60D4BF8C6C07Q38719689-8B470E30-8062-4DB0-A32E-195B720703A5Q38783162-AD49CAE7-126A-4637-8475-7B3ED24CB3F4Q47156672-F17F654D-21FA-4BE1-89B3-93E82A7F4509Q47161308-3EF1ED96-12B8-47DB-8994-777AB19E65F6Q49791882-746EA9C7-88C4-47EC-A166-F624916B5FCC
P2860
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Phase 1 study of the investiga ...... and recommended phase 2 dose.
@en
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib
@nl
type
label
Phase 1 study of the investiga ...... and recommended phase 2 dose.
@en
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib
@nl
prefLabel
Phase 1 study of the investiga ...... and recommended phase 2 dose.
@en
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib
@nl
P2093
P2860
P1476
Phase 1 study of the investiga ...... and recommended phase 2 dose.
@en
P2093
Chia-Chi Lin
Karthik Venkatakrishnan
Lim Soon Thye
Ming Huang Chen
Tae Min Kim
Virginia Kelly
Wee Joo Chng
Won Seog Kim
Xiaofei Zhou
P2860
P2888
P304
P356
10.1007/S10637-015-0258-Y
P50
P577
2015-06-19T00:00:00Z
P6179
1019063283